Wallen N, Kita H, Weiler D, Gleich G J
Department of Immunology, Mayo Clinic, Rochester, MN 55905.
J Immunol. 1991 Nov 15;147(10):3490-5.
Glucocorticoids characteristically induce eosinopenia in vivo and are effective for treating allergic and other eosinophilic disorders. We studied the effect of glucocorticoids on cytokine-induced survival of human eosinophils in vitro. Eosinophils were purified from normal or mildly atopic volunteers by Percoll density gradient and incubated for 4 days in the presence of cytokine plus steroid. Cell viabilities were determined by staining cells with fluorescein diacetate and propidium iodide. In the absence of glucocorticoids, human rIL-5 enhanced eosinophil survival in a dose-dependent manner, from 22 fM for a minimal effect to 2200 fM for maximal effect. When eosinophils were cultured with a submaximal concentration of rIL-5 (220 fM), dexamethasone, methylprednisolone, and hydrocortisone inhibited eosinophil survival in a dose-dependent manner. Inhibition was time-dependent and required at least 2 days' exposure of eosinophils to dexamethasone. Dexamethasone, methylprednisolone, and hydrocortisone at 1000 nM inhibited survival by 88 +/- 2, 66 +/- 9 and 37 +/- 7%. In contrast, estradiol and testosterone (1000 nM) had no effect on eosinophil survival. When eosinophils were incubated with varying concentrations of human rIL-5 and 1000 nM dexamethasone, survival inhibition was reduced at higher concentrations of human rIL-5, and completely abolished by human rIL-5 23,000 fM. Human recombinant granulocyte-macrophage CSF, human rIL-3, and human rIFN-gamma also enhanced eosinophil survival in a dose-dependent manner and dexamethasone (1000 nM) strongly inhibited cell survival when submaximal concentrations of these cytokines were used. The effects of dexamethasone were reversed by higher concentrations of granulocyte-macrophage CSF (10 U/ml) and IL-3 (3 ng/ml). However, even 1000 U/ml IFN-gamma did not overcome dexamethasone inhibition, indicating a difference between the mechanism of eosinophil survival induced by IFN-gamma and other cytokines. These results suggest that glucocorticoids exert a direct, inhibitory effect on eosinophil survival, which may be important in the treatment of allergic and other eosinophilic disorders. Antagonism of this effect by higher amounts of cytokine may be a mechanism for glucocorticoid resistance.
糖皮质激素在体内通常会引发嗜酸性粒细胞减少,并且对治疗过敏性及其他嗜酸性粒细胞相关疾病有效。我们研究了糖皮质激素在体外对细胞因子诱导的人嗜酸性粒细胞存活的影响。通过Percoll密度梯度从正常或轻度特应性志愿者中纯化嗜酸性粒细胞,并在细胞因子加类固醇存在的情况下孵育4天。通过用荧光素二乙酸酯和碘化丙啶对细胞进行染色来测定细胞活力。在没有糖皮质激素的情况下,人重组白细胞介素-5(rIL-5)以剂量依赖性方式提高嗜酸性粒细胞的存活率,最低有效剂量为22飞摩尔,最大有效剂量为2200飞摩尔。当嗜酸性粒细胞用亚最大浓度的rIL-5(220飞摩尔)培养时,地塞米松、甲泼尼龙和氢化可的松以剂量依赖性方式抑制嗜酸性粒细胞的存活。抑制作用具有时间依赖性,并且嗜酸性粒细胞至少需要接触地塞米松2天。1000纳摩尔的地塞米松、甲泼尼龙和氢化可的松分别使存活率降低88±2%、66±9%和37±7%。相比之下,1000纳摩尔的雌二醇和睾酮对嗜酸性粒细胞存活没有影响。当嗜酸性粒细胞与不同浓度的人rIL-5和1000纳摩尔地塞米松一起孵育时,在较高浓度的人rIL-5下存活抑制作用减弱,当rIL-5浓度达到23000飞摩尔时抑制作用完全消除。人重组粒细胞-巨噬细胞集落刺激因子(GM-CSF)、人rIL-3和人干扰素-γ(IFN-γ)也以剂量依赖性方式提高嗜酸性粒细胞的存活率,并且当使用这些细胞因子的亚最大浓度时,地塞米松(1000纳摩尔)强烈抑制细胞存活。较高浓度的GM-CSF(10单位/毫升)和IL-3(3纳克/毫升)可逆转地塞米松的作用。然而,即使1000单位/毫升的IFN-γ也不能克服地塞米松的抑制作用,这表明IFN-γ诱导嗜酸性粒细胞存活的机制与其他细胞因子不同。这些结果表明,糖皮质激素对嗜酸性粒细胞存活具有直接抑制作用,这在治疗过敏性及其他嗜酸性粒细胞相关疾病中可能很重要。较高剂量的细胞因子对这种作用的拮抗可能是糖皮质激素抵抗的一种机制。